bioRxivPathologyPreprint
Isoflavone treatment attenuates cardiovascular-kidney-metabolic (CKM) syndrome symptoms in an experimental model of ovariectomized rats.
Thaís de Souza Lima, Edson de Andrade Pessoa, Amaro Nunes Duarte NetoiD, Cinthya dos Santos CirqueiraiD, Márcia Bastos ConventoiD, Bianca CastinoiD, Andréia Silva de OliveiraiD, Alef AC Santos, Adriana Aparecida Ferraz CarboneliD, Cassiane Dezoti, Maria de Fatima Vattimo, Fernanda Teixeira BorgesiD
Abstract
Cardiovascular-kidney-metabolic (CKM) syndrome represents an integrated spectrum of obesity, type 2 diabetes mellitus, cardiovascular disease, and chronic kidney disease, driven by shared metabolic, inflammatory, and fibrotic mechanisms. Menopause-related estrogen deficiency exacerbates these disturbances, increasing susceptibility to metabolic syndrome and renal injury. This study investigated whether dietary supplementation with soy isoflavones attenuates obesity-associated kidney injury in ovariectomized rats exposed to a high-fat, high-caloric diet. Female Wistar rats underwent bilateral ovariectomy and were assigned to control diet, hipercaloric diet (DH), or DH supplemented with isoflavones (DH+ISO). Metabolic, biochemical, oxidative stress, histopathological, and inflammatory parameters were evaluated over 120 days. The DH diet induced weight gain, hypertension, dyslipidemia, hyperglycemia, impaired renal function, increased oxidative stress, and tubulointerstitial injury, consistent with a CKM phenotype. Isoflavone supplementation did not prevent diet-induced weight gain but attenuated systolic blood pressure elevation and improved lipid and glycemic profiles. Renal function was partially preserved in DH+ISO rats, as evidenced by lower plasma creatinine levels, improved creatinine clearance, reduced urea levels, and decreased urinary peroxide excretion compared with DH animals. Histopathological analysis revealed persistent tubular injury in both DH groups, although inflammatory and oxidative markers were attenuated in isoflavone-treated rats. Immunohistochemistry demonstrated reduced renal IL-6 expression in the DH+ISO group, accompanied by trends toward decreased macrophage infiltration and IL-1{beta} expression. Collectively, these findings indicate that soy isoflavones mitigate metabolic, inflammatory, and oxidative pathways implicated in obesity-related kidney injury in a postmenopausal experimental model. Isoflavone supplementation may represent a complementary therapeutic strategy for attenuating CKM-related renal damage associated with modern diets and estrogen deficiency.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A murine model of cardiovascular-kidney-metabolic syndrome demonstrates compromised limb function in the ischemic hind limb
Saran Lotfollahzadeh, Herreet Paul, … Vipul Chimanlal Chitalia·Kidney360Peer-reviewed·Oct 13, 2025
- Interleukin-17A Mediates Cardiorenal Injury In Oxalate Nephropathy
Moritz I. Wimmer, Martin Reichel, … Hendrik Bartolomaeus·Cardiovascular ResearchPeer-reviewed·Jul 7, 2026
- GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal lipid and energy metabolism homeostasis: revealed by metabolomics
- The non-steroidal mineralocorticoid receptor (MR) antagonist (FINERENONE) reverses Western diet-induced kidney disease by enhancing mitochondrial metabolism and decreasing lipid accumulation and inflammation
Komuraiah Myakala, Xiaoxin X. Wang, … Moshe Levi·American Journal of Physiology-Renal PhysiologyPeer-reviewed·Sep 29, 2025
- Adenine-induced kidney disease alters the cortical bone metabolome of C57BL/6J mice in a manner that depends on sex
Shane Stauffer, Hope D. Welhaven, … Chelsea M. Heveran·bioRxiv·Jun 2, 2025
- Tamoxifen, associated to the conservative CKD treatment, promoted additional antifibrotic effect on experimental hypertensive nephrosclerosis
C. Fanelli, F. M. Ornellas, … I. L. Noronha·bioRxiv·Oct 13, 2022